Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Fred Collins SemitalaJillian L KadotaAllan MusinguziJuliet NabunjeFred WelisheAnne NakitendeLydia AkelloOpira BishopDevika PatelAmanda SammannPayam NahidRobert BelknapMoses R KamyaMargaret A HandleyPatrick Peter John PhillipsAnne KatahoireChristopher Allen BergerNoah KiwanukaAchilles KatambaDavid W DowdyAdithya CattamanchiPublished in: PLoS medicine (2021)
ClinicalTrials.gov NCT03934931.